FDA to Review Neurofilament Lumen as Key Biomarker at Tofersen's Upcoming AdComm Conference

Published Date: 26 Mar 2023

In the Phase 3 study, tofersen did not achieve its primary transformation goal, but it did achieve the goal of SOD1 protein involvement and reduced light exposure.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Lesser-known lobular breast cancer on the rise in U.S. women

2.

Study finds that AI is better at forecasting the risk of developing cancer.

3.

Kate Middleton and Remission: Oncologists Weigh In

4.

According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.

5.

What Role Should Genomic Classifier Testing Play in Prostate Cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot